Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma

BACKGROUND: We aimed to characterize serine protease inhibitor Kazal type 1 (SPINK1) as a gene signature for the early diagnosis, molecular targeting, and prediction of immune checkpoint blockade (ICB) treatment response of hepatocellular carcinoma (HCC). METHODS: The transcriptomics, proteomics, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Jianlong, Ga, Latai, Liu, Yang, Yang, Zhiyi, Wang, Yue, Guo, Xuanze, Ma, Ruichen, Liu, Ruonan, Li, Tianyou, Tang, Zeyao, Wang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341429/
https://www.ncbi.nlm.nih.gov/pubmed/35924241
http://dx.doi.org/10.3389/fimmu.2022.923031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341429/
https://www.ncbi.nlm.nih.gov/pubmed/35924241
http://dx.doi.org/10.3389/fimmu.2022.923031

Ejemplares similares